Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Published: 15 Apr 2026
Author: Towards Healthcare
Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) focus on the science of healthy ageing and announced OneSpaWorld as the newest Niagen Plus provider, engaged to offer pharmaceutical-grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Bioscience’s Significant step of the first cruise ship clinic, marking Niagen partnership, this collaboration brings Niagen IV to guests at sea.
CEO of Niagen Bioscience, Rob Fried, and OneSpaWorld open a new premium channel at sea, strengthen our rapidly expanding Niagen Plus clinic footprint, and support our strategy to scale Niagen IV and injections outside of the U.S.
According to Towards Healthcare, the U.S. intravenous solutions market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 6.19 billion in 2026 to approximately USD 10.82 billion by 2035, representing a compound annual growth rate (CAGR) of 6.4% from 2026 to 2035. Growth is driven by the rise in chronic diseases and the growth in surgical procedures. The advancement in medical technology is likely to enhance efficacy and patient outcomes.
About Niagen Bioscience
It is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-ageing research. This company is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+.
Rob Fried, CEO of Niagen Bioscience, commented, “OneSpaWorld opens a new premium channel at sea, strengthens our rapidly expanding Niagen Plus clinic footprint, and supports our strategy to scale Niagen IV and injections outside of the U.S.”
Collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation, and is distinguished by state-of-the-art laboratories.
About OneSpaWorld
OneSpaWorld holds the leading market position within the cruise industry segment of the international leisure market. It provides health, wellness, aesthetics, fitness, and Medi-Spa services across a broad portfolio of cruise ships and itineraries. It is an FDA-registered outsourcing facility, as a premium onboard OneSpaWorld service, with deployment aligned to ship-specific Medi-Spa operations and applicable regulatory requirements.
CEO, Wells Pharmacy Network, Kris Fishman, stated, “Wells Pharmacy is proud to compound and distribute pharmaceutical-grade Niagen to qualified clinics, supporting this first-of-its-kind rollout at sea with our rigorous compounding and safety standards."
A recent report by Towards Healthcare highlights that the U.S. intravenous solutions market is witnessing a shift due to strategic partnerships and acquisitions, which are gaining momentum as companies seek to expand their product offerings and market presence. There is a market shift towards prefilled and ready-to-use infusion systems, digital health integration, and IoT-enabled devices, which are expected to enhance product portfolios and geographic reach.